The latest development comes after an independent data monitoring committee said in May a similar trial comparing Ibrance plus an endocrine therapy to a standalone endocrine therapy to treat early-stage breast cancer was unlikely to meet the main goal. Ibrance is already approved in the United States to treat certain adult patients with advanced breast cancer which has spread to other parts of the body. …read more
Source:: Yahoo Finance
